One-on-One: TDD Talks to Iain Stuart, PhD, Chief Scientific Officer at Vyne Therapeutics
VYNE Therapeutics recently presented preclinical data on positive preclinical and Phase 1b data of VYN201 in nonsegmental vitiligo at the Society for Investigative Dermatology’s (SID) annual meeting in Dallas, TX. Iain Stuart, PhD, Chief Scientific Officer at Vyne Therapeutics, sat down with the Dermatology Digest to discuss the results, the company’s pipeline, and what we […]